Michor Franziska
Society of Fellows, Harvard University, Cambridge, MA 02138, USA.
Trends Pharmacol Sci. 2007 May;28(5):197-9. doi: 10.1016/j.tips.2007.03.003. Epub 2007 Apr 6.
Progress in understanding the genetic changes that drive tumorigenesis has enabled the development of molecularly targeted anticancer therapy. The first small molecule targeted to a specific protein was imatinib mesylate (Gleevec, STI571), which is used to treat chronic myeloid leukemia (CML). A recent article presents a computational model with which to study the treatment response in CML patients and investigates the effect that imatinib exerts on leukemic stem cells. Here, I discuss insights derived from this study and their implications for imatinib therapy against CML.
在理解驱动肿瘤发生的基因变化方面取得的进展，推动了分子靶向抗癌疗法的发展。首个靶向特定蛋白质的小分子药物是甲磺酸伊马替尼（格列卫，STI571），用于治疗慢性粒细胞白血病（CML）。最近的一篇文章提出了一个计算模型，用于研究CML患者的治疗反应，并探究伊马替尼对白血病干细胞的作用。在此，我将讨论这项研究得出的见解及其对伊马替尼治疗CML的意义。
